DaVita news
The WiseView Research desk's stories that name DaVita, the latest headlines about it, and the trades members of Congress and company insiders have disclosed. The DVA page →
- HeadlineWill DaVita's Q3 Earnings Reflect Improving Treatment Growth Trends?
- HeadlineDaVita Brings Preventive Health Screenings Into Communities to Help Identify Hidden Health Risks
- HeadlineDaVita HealthCare (DVA) Falls More Steeply Than Broader Market: What Investors Need to Know
- HeadlineDaVita Stock Gains 55.6% Year to Date: What's Behind the Rally?
- Market closeS&P 500 edges up, Dow jumps 1% as health care and small caps lead
The Dow rose over 1% and the Russell 2000 gained 1.66% as health care stocks led a broad rally, while the Nasdaq slipped slightly.
- HeadlineDaVita Inc. Schedules 3rd Quarter 2026 Investor Conference Call
- HeadlineDaVita Brings New Clinical Research to ASN Kidney Week 2026, Advancing Evidence for the Next Era of Kidney Care
- HeadlineWhy DaVita HealthCare (DVA) Outpaced the Stock Market Today
- HeadlineDaVita: After A 25% Drop, The Buyback Machine Is Cheap Again
- HeadlineHere's Why You Should Retain DaVita Stock in Your Portfolio for Now
- HeadlineDaVita Activates Emergency Response Efforts Ahead of Hurricane Isaias, Urges Kidney Patients to Prepare Early
- HeadlineDaVita HealthCare (DVA) Laps the Stock Market: Here's Why
- CongressJulie Johnson sold $1,001 - $15,000 of DVA
- CongressJulie Johnson bought $1,001 - $15,000 of DVA
- CongressJulie Johnson sold $1,001 - $15,000 of DVA
- CongressRo Khanna sold $1,001 - $15,000 of DVA
Headlines link to their publishers. Members of Congress disclose ranges, not exact amounts, and may file weeks after the trade; insider filings are open-market purchases and sales from SEC Form 4. For information only, not investment advice.